Financial Data and Key Metrics Changes - Net sales for Q2 were $341 million, a 5% decline compared to Q2 last year [5] - The growth margin rate improved to 8.2%, a 160 basis point increase from 6.6% in the same period last year [10] - Adjusted net income was $6.9 million, or $0.28 per diluted share, compared to $7.4 million, or $0.29 per diluted share last year [12] - Cash generated by operating activities was $6.9 million, marking the eighth consecutive quarter of positive cash flow [13] - The company raised its guidance for fiscal 2026, expecting net sales in the range of $1.4-$1.46 billion, up from previous guidance of $1.35-$1.45 billion [15] Business Line Data and Key Metrics Changes - Medical sales were $96 million, up 15% year-over-year, representing 28% of total company sales [5] - Automotive sales totaled $162 million, down 13% year-over-year, accounting for 48% of total sales [7] - Industrial sales were $83 million, a 5% decrease compared to Q2 last year, making up 24% of total sales [9] Market Data and Key Metrics Changes - The medical vertical showed strong growth, particularly in Poland and Thailand, while North America remained flat [5] - The automotive sector faced declines in North America and China, primarily due to the transfer of an electronic braking program and tariff pressures [7] - Industrial demand in North America decreased, although there was a rebound in Europe due to smart meter sales [9] Company Strategy and Development Direction - The company is focusing on the medical vertical as a key growth area, leveraging its capabilities in a highly regulated industry [6] - A new facility in Indianapolis is part of the strategy to expand manufacturing capacity for medical products [6] - The company is pursuing disciplined acquisitions to enhance geographic reach and manufacturing capabilities [7] - A rebranding to Kimball Solutions reflects the company's evolution beyond traditional manufacturing services [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the medical vertical's growth potential, driven by megatrends such as an aging population and increasing healthcare access [6] - The company is monitoring the North American automotive and industrial markets due to economic concerns and tariff impacts [17] - Future growth in automotive is expected to stabilize as the company anniversaries the end of a significant program [33] Other Important Information - The effective tax rate for Q2 was 47.9%, significantly higher than the previous year's rate of 1.2% [12] - Capital expenditures in Q2 were $18.2 million, primarily for the new facility in Indianapolis [14] - The company has $10.5 million remaining on its share repurchase program, having returned $109.5 million to shareholders since October 2015 [15] Q&A Session Summary Question: What percentage was Nexteer in December? - Nexteer accounted for 20% of sales in December [22] Question: What is the capacity and ramp expectations for the new facility in Indianapolis? - The new facility is 300,000 sq ft, significantly larger than the current footprint, with substantial growth opportunities anticipated [25] Question: How should we think about growth in the automotive piece for Q3 and Q4? - Q3 automotive is expected to be flat to slightly up as the company anniversaries the end of the EB100 program [33] Question: What are the win rates and size of wins across the business? - Win rates remain consistent, with larger programs expected from lift and shift opportunities and CMO discussions [36] Question: How will the new facility impact margins? - The CMO space is expected to be margin accretive long-term, but will initially drag margins due to depreciation and additional expenses [40][41] Question: How do you see cash cycle days play out in the coming quarters? - Cash conversion days are expected to decrease in Q3 from elevated levels in Q2 [44] Question: What are the opportunities in the medical space for acquisitions? - The company is interested in in vitro diagnostics and cardiology as potential areas for expansion [54]